Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Nobuyoshi Hiraoka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4215-4385; OpenAlex author ID A5053946306. Sources: OpenAlex.

Their work

Papers
31 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 4 papers

Papers 31

  1. Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic… Last author DOI 10.1002/jhbp.70106↗
  2. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218348↗
  3. Corrigendum to "MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma" [Cancer Lett. 645, (2026), 21834… Co-author DOI 10.1016/j.canlet.2026.218794↗
  4. Percutaneous abdominal lavage cytology screening reduces non-therapeutic laparotomy in patients with pancreatic cancer considered for curative-intent resection… Co-author DOI 10.1016/j.surg.2026.110444↗
  5. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Co-author DOI 10.1002/cam4.70474↗
  6. Development of a novel co-culture system using human pancreatic cancer cells and human iPSC-derived stellate cells to mimic the characteristics of pancreatic d… Co-author DOI 10.1016/j.bbrc.2023.03.061↗
  7. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  8. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… Co-author DOI 10.1111/den.14423↗
  9. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Last author DOI 10.1038/s41416-021-01639-9↗
  10. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11950-1↗
  11. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11957-8↗
  12. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methyla… Co-author DOI 10.1007/s00432-021-03541-6↗
  13. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  14. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  15. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0242851↗
  16. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/bjs5.50130↗
  17. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Last author DOI 10.18632/oncotarget.26646↗
  18. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envel… Last author DOI 10.1053/j.gastro.2017.03.050↗
  19. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  20. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1634/theoncologist.2016-0194↗
  21. A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. Co-author DOI 10.21873/anticanres.11730↗
  22. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00428-016-2026-6↗
  23. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.623↗
  24. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2015.145↗
  25. A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile. Co-author DOI 10.1371/journal.pone.0132223↗
  26. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. First author DOI 10.1016/j.jconrel.2014.07.053↗
  27. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ctg.2014.5↗
  28. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.53↗
  29. Knowledge discovery for pancreatic cancer using inductive logic programming. Co-author DOI 10.1049/iet-syb.2013.0044↗
  30. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Last author DOI 10.1038/bjc.2013.32↗
  31. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. Last author DOI 10.1371/journal.pone.0055146↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Nara · 10 shared papers, 2016–2026 · strength 1.62
  2. Minoru Esaki · 10 shared papers, 2016–2026 · strength 1.62
  3. Kazuaki Shimada · 17 shared papers, 2013–2022 · strength 1.42
  4. Takuji Okusaka · 9 shared papers, 2014–2026 · strength 1.03
  5. Yoshinori Ino · 9 shared papers, 2013–2022 · strength 0.74
  6. Keisuke Sekine · 3 shared papers, 2023–2026 · strength 0.60
  7. Shunsuke Sugawara · 3 shared papers, 2022–2026 · strength 0.60
  8. Daisuke Ban · 3 shared papers, 2022–2026 · strength 0.60
  9. Kazunori Aoki · 4 shared papers, 2014–2026 · strength 0.51
  10. Chigusa Morizane · 5 shared papers, 2015–2024 · strength 0.49
  11. Yoji Kishi · 4 shared papers, 2016–2022 · strength 0.42
  12. Susumu Hijioka · 2 shared papers, 2023–2026 · strength 0.41
  13. Daiki Yamashige · 2 shared papers, 2023–2026 · strength 0.41
  14. Shota Harai · 2 shared papers, 2023–2026 · strength 0.41
  15. Go Ikeda · 2 shared papers, 2023–2026 · strength 0.41
  16. Hiroyuki Tsunoda · 2 shared papers, 2026 · strength 0.40
  17. Hironori Fukuda · 2 shared papers, 2026 · strength 0.40
  18. Atsushi Ochiai · 2 shared papers, 2026 · strength 0.40
  19. Takeshi Takamoto · 2 shared papers, 2022 · strength 0.30
  20. Kei Kitamura · 2 shared papers, 2022 · strength 0.30
  21. Ryosuke Umino · 1 shared paper, 2026 · strength 0.30
  22. Noriteru Doi · 2 shared papers, 2020–2022 · strength 0.28
  23. Shutaro Hori · 3 shared papers, 2016–2020 · strength 0.27
  24. Makoto Ueno · 3 shared papers, 2015–2023 · strength 0.26
  25. Hideki Ueno · 3 shared papers, 2017–2023 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.